ChromaDex Corp.®, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that it has received equity financing from DSM Venturing, the corporate venture arm of Royal DSM (NYSE Euronext Amsterdam: DSM), the global life sciences and material sciences company.
Frank Jaksch, Jr., CEO and cofounder of ChromaDex, commented, "It is with great pride and enthusiasm that we welcome DSM as a strategic investor in ChromaDex. We believe the investment demonstrates their confidence in the future of ChromaDex as well as our unique business model of acquiring and commercializing novel ingredient technologies."
Pieter Wolters, managing director DSM Venturing said, "We are pleased to invest in ChromaDex and thereby support Frank Jaksch and the entire ChromaDex team in the expansion of their business. We look forward to a mutually beneficial relationship."
The financial details of the investment were not disclosed.